Media stories about Psychemedics Corporation (NASDAQ:PMD) have trended somewhat negative on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Psychemedics Corporation earned a coverage optimism score of -0.06 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.3905539925143 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Psychemedics Corporation (NASDAQ PMD) traded up 0.71% on Friday, hitting $18.43. The stock had a trading volume of 33,483 shares. The firm’s 50-day moving average price is $20.57 and its 200-day moving average price is $21.51. The firm has a market cap of $101.22 million, a P/E ratio of 13.45 and a beta of 1.02. Psychemedics Corporation has a 1-year low of $13.81 and a 1-year high of $27.99.

Psychemedics Corporation (NASDAQ:PMD) last released its quarterly earnings results on Wednesday, August 2nd. The company reported $0.16 earnings per share for the quarter. The firm had revenue of $9.68 million during the quarter. Psychemedics Corporation had a return on equity of 47.94% and a net margin of 17.59%. On average, equities research analysts predict that Psychemedics Corporation will post $0.93 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Somewhat Negative Media Coverage Somewhat Unlikely to Affect Psychemedics Corporation (PMD) Stock Price” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/somewhat-negative-media-coverage-somewhat-unlikely-to-affect-psychemedics-corporation-pmd-stock-price/1601598.html.

In other news, VP Michael I. Schaffer sold 7,548 shares of Psychemedics Corporation stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $20.41, for a total value of $154,054.68. Following the completion of the sale, the vice president now directly owns 41,273 shares of the company’s stock, valued at approximately $842,381.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael I. Schaffer sold 4,400 shares of Psychemedics Corporation stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $20.37, for a total value of $89,628.00. Following the completion of the sale, the vice president now directly owns 41,273 shares of the company’s stock, valued at $840,731.01. The disclosure for this sale can be found here. Insiders sold a total of 12,929 shares of company stock valued at $264,441 over the last three months. Insiders own 8.60% of the company’s stock.

Psychemedics Corporation Company Profile

Psychemedics Corporation (Psychemedics) provides hair testing for drugs of abuse, utilizing a hair analysis method involving digestion of hair, enzyme immunoassay (EIA) technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company operates in drug testing services segment.

Insider Buying and Selling by Quarter for Psychemedics Corporation (NASDAQ:PMD)

Receive News & Ratings for Psychemedics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.